Clearmind Medicine Completes Treatment And Follow-Up Of 18 Participants In Ongoing FDA-Approved Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of Alcohol Use Disorder

Company completed treatment in four additional participate at its Israel clinical site

Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

This milestone reflects continued positive progress and strong momentum in the multinational, multicenter study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD.

The Company also wishes to announce that four additional participants have been successfully treated at the clinical center in Tel Aviv, further expanding enrollment and demonstrating the operational strength of the Israeli sites in the trial.